Compare JUBILANT LIFE SCIENCES with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES GSK PHARMA JUBILANT LIFE SCIENCES/
GSK PHARMA
 
P/E (TTM) x 15.2 52.1 29.1% View Chart
P/BV x 1.8 11.0 16.1% View Chart
Dividend Yield % 0.8 1.4 58.3%  

Financials

 JUBILANT LIFE SCIENCES   GSK PHARMA
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-19
GSK PHARMA
Mar-19
JUBILANT LIFE SCIENCES/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs8983,595 25.0%   
Low Rs6181,253 49.3%   
Sales per share (Unadj.) Rs572.0184.7 309.8%  
Earnings per share (Unadj.) Rs36.226.3 137.8%  
Cash flow per share (Unadj.) Rs59.529.2 204.1%  
Dividends per share (Unadj.) Rs4.5020.00 22.5%  
Dividend yield (eoy) %0.60.8 72.0%  
Book value per share (Unadj.) Rs301.9126.3 239.0%  
Shares outstanding (eoy) m159.28169.40 94.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.313.1 10.1%   
Avg P/E ratio x20.992.2 22.7%  
P/CF ratio (eoy) x12.783.1 15.3%  
Price / Book Value ratio x2.519.2 13.1%  
Dividend payout %12.476.1 16.3%   
Avg Mkt Cap Rs m120,694410,626 29.4%   
No. of employees `0002.45.0 48.2%   
Total wages/salary Rs m19,2605,372 358.5%   
Avg. sales/employee Rs Th38,120.66,306.7 604.4%   
Avg. wages/employee Rs Th8,058.41,083.1 744.0%   
Avg. net profit/employee Rs Th2,414.3898.0 268.9%   
INCOME DATA
Net Sales Rs m91,10831,281 291.3%  
Other income Rs m3571,023 34.9%   
Total revenues Rs m91,46632,304 283.1%   
Gross profit Rs m17,3906,009 289.4%  
Depreciation Rs m3,709486 763.2%   
Interest Rs m2,1986 36,635.0%   
Profit before tax Rs m11,8406,540 181.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-2,802287 -976.4%   
Tax Rs m3,2682,373 137.7%   
Profit after tax Rs m5,7704,454 129.5%  
Gross profit margin %19.119.2 99.4%  
Effective tax rate %27.636.3 76.1%   
Net profit margin %6.314.2 44.5%  
BALANCE SHEET DATA
Current assets Rs m45,84820,061 228.5%   
Current liabilities Rs m20,89714,543 143.7%   
Net working cap to sales %27.417.6 155.2%  
Current ratio x2.21.4 159.0%  
Inventory Days Days5757 100.0%  
Debtors Days Days5114 362.3%  
Net fixed assets Rs m65,49814,343 456.7%   
Share capital Rs m1591,694 9.4%   
"Free" reserves Rs m47,93019,704 243.2%   
Net worth Rs m48,08921,398 224.7%   
Long term debt Rs m42,4292 2,121,445.0%   
Total assets Rs m114,68539,113 293.2%  
Interest coverage x6.41,091.0 0.6%   
Debt to equity ratio x0.90 943,981.1%  
Sales to assets ratio x0.80.8 99.3%   
Return on assets %6.911.4 60.9%  
Return on equity %12.020.8 57.6%  
Return on capital %12.431.9 38.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,422534 2,326.2%   
Fx outflow Rs m17,2277,091 242.9%   
Net fx Rs m-4,805-6,557 73.3%   
CASH FLOW
From Operations Rs m11,2153,994 280.8%  
From Investments Rs m-10,118-1,433 705.9%  
From Financial Activity Rs m6,574-3,584 -183.5%  
Net Cashflow Rs m7,612-1,023 -744.0%  

Share Holding

Indian Promoters % 45.6 0.0 -  
Foreign collaborators % 3.5 50.7 6.9%  
Indian inst/Mut Fund % 8.7 10.2 85.3%  
FIIs % 21.2 23.8 89.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 15.4 137.0%  
Shareholders   23,815 102,036 23.3%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   DISHMAN PHARMA  ELDER PHARMA  ALEMBIC LTD  PANACEA BIOTECH  WOCKHARDT  

Compare JUBILANT LIFE SCIENCES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Sep 20, 2019 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 8-QTR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS